Cargando…

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation

Acute lymphoblastic leukemia (ALL) is one of the most common hematological malignancies at pediatric ages and is characterized by different chromosomal rearrangements and genetic abnormalities involved in the differentiation and proliferation of lymphoid precursor cells. Brusatol is a quassinoid pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorge, Joana, Magalhães, Nisa, Alves, Raquel, Lapa, Beatriz, Gonçalves, Ana Cristina, Sarmento-Ribeiro, Ana Bela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496058/ https://www.ncbi.nlm.nih.gov/pubmed/36140308 http://dx.doi.org/10.3390/biomedicines10092207

Ejemplares similares

PB1822: INHIBITION OF THE DNA DAMAGE RESPONSE: A POSSIBLE NEW ROUTE IN ACUTE MYELOBLASTIC LEUKEMIA TREATMENT
por: Lapa, Beatriz, et al.
Publicado: (2023)

Brusatol
por: Hu, Shu-Zhi, et al.
Publicado: (2012)

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
por: Lapa, Beatriz, et al.
Publicado: (2023)

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023)

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023)

Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells
por: Costa, Maria Inês, et al.
Publicado: (2022)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies
por: Jorge, Joana, et al.
Publicado: (2023)

AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells
por: Lapa, Beatriz Santos, et al.
Publicado: (2023)

Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia
por: Alves, Raquel, et al.
Publicado: (2022)

Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines
por: Alves, Raquel, et al.
Publicado: (2023)

The toxic effects and possible mechanisms of Brusatol on mouse oocytes
por: Ma, Rujun, et al.
Publicado: (2017)

Brusatol, an NRF2 inhibitor for future cancer therapeutic
por: Cai, Sabrina J., et al.
Publicado: (2019)

Platelet Membrane Proteins as Pain Biomarkers in Patients with Severe Dementia
por: Ribeiro, Hugo, et al.
Publicado: (2023)

Monocytes in the Characterization of Pain in Palliative Patients with Severe Dementia—A Pilot Study
por: Ribeiro, Hugo, et al.
Publicado: (2023)

Brusatol: A potential anti-tumor quassinoid from Brucea javanica
por: Yu, Xiao-qi, et al.
Publicado: (2020)

MicroRNA signature refine response prediction in CML
por: Alves, Raquel, et al.
Publicado: (2019)

Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas
por: Wu, Zerui, et al.
Publicado: (2021)

Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1
por: Dai, Zhang’an, et al.
Publicado: (2021)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
por: Gonçalves, Ana Cristina, et al.
Publicado: (2021)

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
por: Martins, Ivana, et al.
Publicado: (2021)

Larvicidal Activity of Brusatol Isolated from Brucea javanica (L) Merr on Culex quinquefasciatus
por: SUTININGSIH, Dwi, et al.
Publicado: (2019)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

Zinc: From Biological Functions to Therapeutic Potential
por: Costa, Maria Inês, et al.
Publicado: (2023)

Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis
por: Alves, Raquel, et al.
Publicado: (2022)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
por: Sun, Xiaohui, et al.
Publicado: (2016)

Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies
por: Lu, Zheng, et al.
Publicado: (2017)

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018)

Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma
por: Lee, Jong Hyun, et al.
Publicado: (2020)

A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma
por: Farinha, Dina, et al.
Publicado: (2021)

Redox-sensitive micelles composed of disulfide-linked Pluronic-linoleic acid for enhanced anticancer efficiency of brusatol
por: Zhang, Jinming, et al.
Publicado: (2018)

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2018)

Brusatol Derivative–34 Attenuates Allergic Airway Inflammation Via Inhibition of the Spleen Tyrosine Kinase Pathway
por: Ding, Yasi, et al.
Publicado: (2021)

Brusatol Inhibits Proliferation and Metastasis of Colorectal Cancer by Targeting and Reversing the RhoA/ROCK1 Pathway
por: Lu, Rui-jin, et al.
Publicado: (2022)

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)

Antitumoral effect of farnesiltransferase and mtor inhibitors in hepatocellular carcinoma: in vitro studies
por: Araújo, Ana M, et al.
Publicado: (2010)

UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response
por: Wang, Mei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3mg187pelqe0fkk5hgt9j7dstm